300 592

Cited 9 times in

Establishment of Chemosensitivity Tests in Triple-Negative and BRCA-mutated Breast Cancer Patient-Derived Xenograft Models

DC Field Value Language
dc.contributor.author김승일-
dc.contributor.author김주흥-
dc.contributor.author김지예-
dc.contributor.author박세호-
dc.contributor.author박형석-
dc.contributor.author손주혁-
dc.date.accessioned2020-07-09T16:41:25Z-
dc.date.available2020-07-09T16:41:25Z-
dc.date.issued2019-12-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/178107-
dc.description.abstractPurpose: A patient-derived xenograft (PDX) model is an in vivo animal model which provides biological and genomic profiles similar to a primary tumor. The characterization of factors that influence the establishment of PDX is crucial. Furthermore, PDX models can provide a platform for chemosensitivity tests to evaluate the effectiveness of a target agent before applying it in clinical trials. Methods: We implanted 83 cases of breast cancer into NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic mice, to develop PDX models. Clinicopathological factors of primary tumors were reviewed to identify the factors affecting engraftment success rates. After the establishment of PDX models, we performed olaparib and carboplatin chemosensitivity tests. We used PDX models from triple-negative breast cancer (TNBC) with neoadjuvant chemotherapy and/or germline BRCA1 mutations in chemosensitivity tests. Results: The univariate analyses (p<0.05) showed factors which were significantly associated with successful engraftment of PDX models include poor histologic grade, presence of BRCA mutation, aggressive diseases, and death. Factors which were independently associated with successful engraftment of PDX models on multivariate analyses include poor histologic grade and aggressive diseases status. In chemosensitivity tests, a PDX model with the BRCA1 L1780P mutation showed partial response to olaparib and complete response to carboplatin. Conclusions: Successful engraftment of PDX models was significantly associated with aggressive diseases. Patients who have aggressive diseases status, large tumors, and poor histologic grade are ideal candidates for developing successful PDX models. Chemosensitivity tests using the PDX models provide additional information about alternative treatment strategies for residual TNBC after neoadjuvant chemotherapy.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPublic Library of Science-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAnimals-
dc.subject.MESHAntineoplastic Agents / therapeutic use*-
dc.subject.MESHBRCA1 Protein / genetics*-
dc.subject.MESHCarboplatin / therapeutic use*-
dc.subject.MESHDisease Models, Animal-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMice-
dc.subject.MESHMice, Inbred NOD-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHPhthalazines / therapeutic use*-
dc.subject.MESHPiperazines / therapeutic use*-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTriple Negative Breast Neoplasms / drug therapy*-
dc.subject.MESHTriple Negative Breast Neoplasms / genetics-
dc.subject.MESHTriple Negative Breast Neoplasms / pathology-
dc.subject.MESHXenograft Model Antitumor Assays*-
dc.titleEstablishment of Chemosensitivity Tests in Triple-Negative and BRCA-mutated Breast Cancer Patient-Derived Xenograft Models-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorHyung Seok Park-
dc.contributor.googleauthorJeong Dong Lee-
dc.contributor.googleauthorJee Ye Kim-
dc.contributor.googleauthorSeho Park-
dc.contributor.googleauthorJoo Heung Kim-
dc.contributor.googleauthorHyun Ju Han-
dc.contributor.googleauthorYeon A Choi-
dc.contributor.googleauthorAe Ran Choi-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorSeung Il Kim-
dc.identifier.doi10.1371/journal.pone.0225082-
dc.contributor.localIdA00658-
dc.contributor.localIdA04910-
dc.contributor.localIdA00984-
dc.contributor.localIdA01524-
dc.contributor.localIdA01753-
dc.contributor.localIdA01995-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid31821346-
dc.contributor.alternativeNameKim, Seung Il-
dc.contributor.affiliatedAuthor김승일-
dc.contributor.affiliatedAuthor김주흥-
dc.contributor.affiliatedAuthor김지예-
dc.contributor.affiliatedAuthor박세호-
dc.contributor.affiliatedAuthor박형석-
dc.contributor.affiliatedAuthor손주혁-
dc.citation.volume14-
dc.citation.number12-
dc.citation.startPagee0225082-
dc.identifier.bibliographicCitationPLOS ONE, Vol.14(12) : e0225082, 2019-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.